ImmunityBio, Inc.
NASDAQ: IBRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Richard Gerald Adcock
- Employees
- 671
- Headquarters
- San Diego, United States
- IPO year
- 2015
- Market cap
- $7.7B
- Website
- https://immunitybio.com
Loading IBRX…
Loading profile data…Frequently asked questions about IBRX
What does ImmunityBio, Inc. (IBRX) do?
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platf...
Where does IBRX trade?
ImmunityBio, Inc. (IBRX) trades on the NASDAQ Global Select.
What sector is IBRX in?
ImmunityBio, Inc. (IBRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ImmunityBio, Inc.?
Richard Gerald Adcock is the chief executive officer of ImmunityBio, Inc. (IBRX).
Where is ImmunityBio, Inc. headquartered?
ImmunityBio, Inc. is headquartered in United States.
Does IBRX pay a dividend?
ImmunityBio, Inc. (IBRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IBRX go public?
ImmunityBio, Inc. (IBRX) completed its initial public offering in 2015.